Medpace Holdings Inc (NASDAQ:MEDP) – Stock analysts at William Blair lifted their Q1 2018 earnings per share (EPS) estimates for shares of Medpace in a research note issued to investors on Thursday. William Blair analyst J. Kreger now anticipates that the company will earn $0.47 per share for the quarter, up from their prior estimate of $0.39. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Medpace’s Q2 2018 earnings at $0.49 EPS, Q3 2018 earnings at $0.52 EPS and Q4 2018 earnings at $0.53 EPS.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a return on equity of 10.00% and a net margin of 6.44%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 earnings per share.

A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird boosted their price objective on Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. BidaskClub lowered Medpace from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. KeyCorp reissued a “hold” rating on shares of Medpace in a research note on Tuesday, October 17th. Finally, Jefferies Group boosted their price objective on Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $36.60.

Medpace (MEDP) opened at $38.05 on Friday. The firm has a market capitalization of $1,410.00 and a price-to-earnings ratio of 55.14. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68. Medpace has a 12 month low of $21.76 and a 12 month high of $39.64.

Several institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP lifted its stake in shares of Medpace by 30.9% in the 3rd quarter. Susquehanna International Group LLP now owns 9,947 shares of the company’s stock valued at $317,000 after purchasing an additional 2,347 shares during the last quarter. GSA Capital Partners LLP lifted its stake in shares of Medpace by 173.8% in the 3rd quarter. GSA Capital Partners LLP now owns 28,200 shares of the company’s stock valued at $900,000 after purchasing an additional 17,900 shares during the last quarter. Convergence Investment Partners LLC lifted its stake in shares of Medpace by 13.4% in the 3rd quarter. Convergence Investment Partners LLC now owns 24,819 shares of the company’s stock valued at $792,000 after purchasing an additional 2,940 shares during the last quarter. OxFORD Asset Management LLP lifted its stake in shares of Medpace by 21.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 98,605 shares of the company’s stock valued at $3,135,000 after purchasing an additional 17,161 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Medpace by 42.8% in the 3rd quarter. Wells Fargo & Company MN now owns 10,354 shares of the company’s stock valued at $330,000 after purchasing an additional 3,104 shares during the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total value of $138,736,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 25.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Q1 2018 EPS Estimates for Medpace Holdings Inc (MEDP) Lifted by William Blair” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/q1-2018-eps-estimates-for-medpace-holdings-inc-medp-lifted-by-william-blair/1804295.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.